Crossmark

Reply to the letter to the editor “Pembrolizumab added to neoadjuvant chemotherapy may improve pathological complete response in androgen-receptor positive and low tumor-infiltrating lymphocytes triple-negative breast cancer patients”

Crossref DOI link: https://doi.org/10.1007/s12282-025-01703-9

Published Online: 2025-04-13

Published Print: 2025-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ushigusa, Takeshi https://orcid.org/0000-0002-5946-3742
Yoshida, Atsushi https://orcid.org/0000-0001-5536-132X
Kanomata, Naoki https://orcid.org/0000-0002-0172-4524
License Information

Text and Data Mining valid from 2025-04-13

Version of Record valid from 2025-04-13
More Information

Article History

Received: 24 February 2025

Accepted: 29 March 2025

First Online: 13 April 2025

Declarations

:

: The authors declare no conflicts of interest.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below